IceCure Medical (ICCM) Current Deferred Revenue (2022 - 2025)

IceCure Medical (ICCM) has reported Current Deferred Revenue for 4 consecutive years, with $255000.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Current Deferred Revenue fell 23.65% year-over-year to $255000.0 in Q4 2025; TTM through Dec 2025 was $255000.0, a 23.65% decrease from a year earlier, with the FY2025 full-year figure at $255000.0, down 23.65% from the prior year.
• Current Deferred Revenue was $255000.0 for Q4 2025 at IceCure Medical, down from $334000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $646000.0 in Q4 2022 and troughed at $187000.0 in Q4 2023.
• A 4-year average of $355500.0 and a median of $294500.0 in 2024 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue sank 71.05% in 2023 and jumped 78.61% in 2024, its largest moves.
• Over 4 years, Current Deferred Revenue stood at $646000.0 in 2022, then slumped by 71.05% to $187000.0 in 2023, then jumped by 78.61% to $334000.0 in 2024, then dropped by 23.65% to $255000.0 in 2025.
• The last three Current Deferred Revenue figures came in at $255000.0 (Q4 2025), $334000.0 (Q4 2024), and $187000.0 (Q4 2023), per Business Quant data.